Welcome to our dedicated page for Bluebird Bio news (Ticker: BLUE), a resource for investors and traders seeking the latest updates and insights on Bluebird Bio stock.
Bluebird bio news centers on the company's commercial-stage gene therapy business for severe genetic diseases and its completed acquisition by funds managed by Carlyle and SK Capital. The company developed and delivered FDA-approved therapies for sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy, with recurring updates tied to commercial delivery, manufacturing infrastructure, treatment-center support, payer partnerships, and patient access.
Company news also documents the transaction process that ended Bluebird bio's public listing, including tender-offer communications, merger-agreement amendments, capital-structure matters, governance actions, and the cessation of trading in its common stock after the acquisition closed.
bluebird bio (Nasdaq: BLUE) will host a live webcast on December 7, 2020, at 7:00 p.m. ET to discuss clinical data from the 62nd American Society of Hematology Annual Meeting. Investors can join by calling (844) 825-4408 in the U.S. or +1 (315) 625-3227 internationally, using conference ID 3493595. The webcast will be accessible through the Investors & Media section of the company's website and will be available for 90 days after the event. bluebird bio focuses on gene therapies for severe genetic diseases and cancer.
bluebird bio (Nasdaq: BLUE) announced that data from its gene and cell therapy programs for sickle cell disease (SCD), transfusion-dependent beta-thalassemia (TDT), and multiple myeloma (MM) will be presented at the 62nd ASH Annual Meeting, held virtually from December 5-8, 2020. Key presentations include updated results from the Phase 1/2 HGB-206 study of LentiGlobin™ for SCD and data from multiple studies on betibeglogene autotemcel for TDT and anti-BCMA CAR T cell therapies for MM. These studies highlight improvements in health-related quality of life and long-term efficacy for treatment options.
bluebird bio (Nasdaq: BLUE) announced that the European Medicines Agency (EMA) has accepted its marketing authorization application (MAA) for its investigational gene therapy, elivaldogene autotemcel (eli-cel), aimed at treating cerebral adrenoleukodystrophy (CALD), a severe neurodegenerative disorder. This therapy could be the first to use patients' own stem cells, potentially reducing immune risks. The MAA is based on data from clinical studies, including the Phase 2/3 Starbeam study. The FDA has granted eli-cel several designations, and bluebird bio aims to submit a Biologics License Application in mid-2021.
bluebird bio (NASDAQ: BLUE) announced that its management team will participate in the Jefferies Cell Therapy Virtual Summit on October 6 at 2:00 p.m. ET. Investors can access the live webcast on the bluebird bio website under the Investors & Media section. The presentation will also be available for replay for 90 days after the event. Known for pioneering gene therapy, bluebird bio focuses on severe genetic diseases and cancer, aiming to improve healthcare access and education.